Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer...

Related Keywords

Arizona ,United States ,Kansas ,Heinz Josef Lenz ,Acta Oncologica ,Mark Erlander ,Amy Jobe ,Vicki Kelemen ,Joyce Allaire ,Katherinel Ruffner ,Cardiff Oncology Inc ,Inova Schar Cancer Institute ,Cancer Center ,Prnewswire Cardiff Oncology Inc ,Nasdaq ,Exchange Commission ,Kansas University Medical Center ,Lifesci Communications ,Norris Comprehensive Cancer Center ,Comprehensive Cancer Center ,American Society ,Cardiff Oncology ,Second Line Treatment ,Line Treatment ,Metastatic Colorectal Cancer ,Mayo Clinic ,Inova Schar Cancer ,Lancet Oncol ,Correspondence Lancet Oncol June ,Polo Like Kinase ,Private Securities Litigation Reform Act ,Oncology Contact ,Nc ,